| dc.contributor.author | Girón Ortega, José Antonio | |
| dc.contributor.author | Márquez Coello, María de las Mercedes | |
| dc.contributor.author | Gutiérrez Saborido, Daniel | |
| dc.contributor.author | Arizcorreta Yarza, Ana | |
| dc.contributor.author | Cuesta Sancho, Sara | |
| dc.contributor.author | Girón González, José Antonio | |
| dc.contributor.other | Biomedicina, Biotecnología y Salud Pública | es_ES |
| dc.contributor.other | Medicina | es_ES |
| dc.date.accessioned | 2024-11-21T10:34:11Z | |
| dc.date.available | 2024-11-21T10:34:11Z | |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 1435-4373 | |
| dc.identifier.issn | 0934-9723 | |
| dc.identifier.uri | http://hdl.handle.net/10498/33879 | |
| dc.description.abstract | To analyze the modifications of CD4 T cell, CD4/CD8 ratio, and serum levels of soluble CD14 (sCD14) in HIV/HCV-coinfected patients after treatment with direct anti-HCV antiviral agents. Consecutive cases of HIV/HCV-coinfected patients, attended at the University Hospital, who achieved sustained virological responses with interferon-free hepatitis C antiviral drugs, were analyzed. Thirty-five percent of patients (n = 39) had been diagnosed with liver cirrhosis. The evaluation criteria were changes in CD4 T-cell counts and percentages and inflammation (measured by serum sCD14 levels) or immune activation indexes (determined by CD4/CD8 ratio) from beginning anti-HCV therapy to 12 months later. One hundred twelve patients were included (87% male; median age, 54 years; median time from the infection diagnosis, 22 years; previous drug users, 87%). Significant increases in CD4 T cell count and percentage were detected only in individuals without liver cirrhosis. No significant differences in CD4/CD8 ratios or sCD14 levels were observed in patients with or without cirrhosis. The proportion of patients with less than 500 CD4 T cell/mm3 before therapy who achieved more than 500 CD4 T cell/mm3 after it increased only in the group without liver cirrhosis. The finding that CD4 T cell count and percentage were improved only in patients without liver cirrhosis supports the idea that treatment against HCV in HIV/HCV-coinfected patients is needed in the early phases of liver disease. | es_ES |
| dc.description.sponsorship | Secretaría General de Investigación, Desarrollo e Innovación en Salud, Junta de Andalucía, Iniciativa Territorial Integrada 2014-2020 para la provincia de Cádiz (No PI-0076-2017), Spain. Co-financed by FEDER (Fondo Europeo de Desarrollo Regional). | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | SPRINGER | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Eur J Clin Microbiol Infect Dis. 2021 Sep;40(9):1863-1871. | es_ES |
| dc.subject | HIV infection | es_ES |
| dc.subject | Hepatitis C virus | es_ES |
| dc.subject | CD4 T cells | es_ES |
| dc.subject | CD8 T cells | es_ES |
| dc.subject | CD4/CD8 ratio | es_ES |
| dc.subject | Soluble CD14 | es_ES |
| dc.subject | Direct-acting antiviral agents | es_ES |
| dc.subject | Sustained viral response | es_ES |
| dc.title | Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | closed access | es_ES |
| dc.identifier.doi | 10.1007/s10096-021-04237-y. | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F01361/ES/INFECCION POR VIH, FORMACION DE NETS Y ATEROSCLEROSIS/ | es_ES |
| dc.type.hasVersion | VoR | es_ES |